title: [The first experience of the use the Russian Β-interferon-1b biosimilar (infibeta) in the daily practice of the Moscow Center of Multiple Sclerosis].
abstract: We summarized the 1-year experience of using the Russian Β-interferon-1b biosimilar (infibeta) in 123 patients including 65 patients with relapsing-remitting multiple sclerosis (RMS) and 58 patients with secondary progressive multiple sclerosis (SPMS). The significant decrease in the frequency of exacerbations per year was seen during the first year of treatment. We also noted the stabilization of the process of disability without the rise in EDSS scores in more than 50% of patients. Good tolerability comparable to that of the original drug was observed during the first year of treatment. There was no refusal from therapy with infibeta, which indicated sufficiently strong adherence to this type of treatment.
authors.forename: E V
authors.initials: EV
authors.lastname: Popova
authors.forename: A N
authors.initials: AN
authors.lastname: Boĭko
authors.forename: M V
authors.initials: MV
authors.lastname: Davydovskaia
authors.forename: T L
authors.initials: TL
authors.lastname: Demina
authors.forename: T M
authors.initials: TM
authors.lastname: Kukel'
authors.forename: N Iu
authors.initials: NIu
authors.lastname: Lashch
authors.forename: N F
authors.initials: NF
authors.lastname: Popova
authors.forename: N V
authors.initials: NV
authors.lastname: Khachanova
authors.forename: S G
authors.initials: SG
authors.lastname: Shchur
authors.forename: E I
authors.initials: EI
authors.lastname: Gusev
mesh_terms: D000276:Adjuvants, Immunologic / Q000008:administration & dosage*; D000293:Adolescent; D000328:Adult; D002648:Child; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007279:Injections, Subcutaneous; D000068576:Interferon beta-1b; D016899:Interferon-beta / Q000008:administration & dosage*; D008297:Male; D008875:Middle Aged; D009031:Moscow; D009103:Multiple Sclerosis / Q000188:drug therapy*; D011994:Recombinant Proteins; D012189:Retrospective Studies; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D000276:Adjuvants, Immunologic; D011994:Recombinant Proteins; D000068576:Interferon beta-1b; D016899:Interferon-beta